Zepbound is FDA-approved for chronic weight management in adults and is dosed weekly by subcutaneous injection, starting at 2.5 mg and escalating in 2.5 mg increments every 4 weeks up to a maximum of 15 mg. The right Zepbound dose for an individual depends on tolerability, weight loss response, and clinical goals, and escalation always happens under a prescribing clinician’s supervision.
What Zepbound Is and How It Works
Zepbound is the brand name for tirzepatide when prescribed for chronic weight management. It is made by Eli Lilly and received FDA approval in late 2023. Tirzepatide is a dual GIP and GLP-1 receptor agonist, meaning it activates two incretin hormone pathways that regulate insulin release, gastric emptying, and appetite. Zepbound is indicated for adults with a BMI of 30 or greater, or a BMI of 27 or greater plus at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia.
Mounjaro, the same molecule, is FDA-approved for type 2 diabetes rather than weight management. The two products are not interchangeable for insurance purposes even though the active ingredient is identical.
Standard Zepbound Dose Schedule
The FDA-labeled titration begins at 2.5 mg weekly and increases every 4 weeks until the maintenance dose is reached. There are three approved maintenance doses: 5 mg, 10 mg, and 15 mg. Intermediate steps of 7.5 mg and 12.5 mg exist as titration doses but are not approved as long-term maintenance options.
| Week Range | Dose | Purpose | Notes |
|---|---|---|---|
| Weeks 1 to 4 | 2.5 mg weekly | Titration, not therapeutic | Minimizes GI side effects |
| Weeks 5 to 8 | 5 mg weekly | First maintenance option | May stop here if goals met |
| Weeks 9 to 12 | 7.5 mg weekly | Titration step | Not a long-term maintenance dose |
| Weeks 13 to 16 | 10 mg weekly | Second maintenance option | May stop here if goals met |
| Weeks 17 to 20 | 12.5 mg weekly | Titration step | Not a long-term maintenance dose |
| Week 21 onward | 15 mg weekly | Maximum maintenance dose | Greatest average weight loss |
Efficacy at Different Zepbound Doses
The SURMOUNT-1 trial, which randomized 2,539 adults with obesity but without diabetes to Zepbound 5 mg, 10 mg, 15 mg, or placebo over 72 weeks, provides the clearest dose-response data.
- 5 mg: Average 15 percent body weight loss
- 10 mg: Average 19.5 percent body weight loss
- 15 mg: Average 20.9 percent body weight loss
- Placebo: Average 3.1 percent body weight loss
Clinically meaningful weight loss is achievable at any of the three maintenance doses. Higher doses produce more weight loss on average, but individual responses vary widely. Some patients meet their goals at 5 mg; others benefit from escalating to 15 mg. The right dose is one that achieves target weight loss with tolerable side effects.
When to Stay at a Lower Dose
Not every Zepbound user needs to reach 15 mg. Your prescriber may recommend staying at 5 mg or 10 mg if you achieve your weight loss goal, experience significant side effects at higher doses, have already lost 10 to 15 percent of body weight and prefer to maintain rather than continue losing, or have competing clinical concerns. Staying at a lower dose also reduces monthly medication cost in some insurance structures. Your broader metabolic picture, including A1C levels and blood pressure, often informs the decision.
How to Inject Your Zepbound Dose
Zepbound is supplied as a single-dose pen or vial. The pen is pre-filled and delivers one dose per device. Injection is subcutaneous, meaning into the fatty tissue just under the skin, typically in the abdomen, thigh, or upper arm. Rotate sites weekly to prevent tissue changes. Pens should be stored in the refrigerator between 36°F and 46°F and used within 21 days if kept at room temperature (up to 86°F). Protect from direct light and do not freeze.
If you miss a dose, take it within 4 days of the scheduled day; otherwise, skip the missed dose and resume the regular schedule. Do not take two doses within 3 days of each other.
Side Effects by Dose
The most common side effects of Zepbound are gastrointestinal: nausea, diarrhea, constipation, vomiting, and abdominal pain. These tend to be worse during the first weeks at each new dose and usually improve within 2 to 4 weeks. In SURMOUNT-1, side-effect rates were broadly similar across the 5, 10, and 15 mg doses, though the severity of nausea and vomiting trended higher at 15 mg.
Less common but serious side effects include pancreatitis, gallbladder disease, hypoglycemia (particularly when combined with insulin or sulfonylureas), acute kidney injury from dehydration, and severe allergic reactions. Zepbound carries a boxed warning for thyroid C-cell tumors based on rodent studies and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2. Always review current safety information on the FDA drug information portal.
Who Should Not Start or Escalate Zepbound
Zepbound is not recommended during pregnancy or while planning pregnancy; discontinue at least 2 months before a planned pregnancy. Patients with severe gastrointestinal disease, a history of pancreatitis, active gallbladder disease, or severe renal impairment require careful evaluation. Pediatric use is not approved. If you are taking medications that can cause hypoglycemia, your prescriber will likely adjust those doses as Zepbound escalates. Consider integrating dose decisions with broader lifestyle planning on our treatment hub.
The Bottom Line
Zepbound is dosed once weekly, starting at 2.5 mg and titrating up to a maximum of 15 mg in 4-week intervals. Each of the three approved maintenance doses (5, 10, and 15 mg) produces clinically meaningful weight loss, with higher doses offering greater average results at the cost of somewhat more side effects. Your prescriber will individualize the escalation pace and maintenance dose based on your response, tolerability, and goals.
Medical disclaimer: This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or qualified healthcare provider with any questions about a medical condition or treatment.
